Lapelga 6 mg (Pegfilgrastim SOLUTION) 6 MG

Lapelga 6 mg is a subcutaneous solution containing pegfilgrastim, used to support white blood cell production during chemotherapy. This medication helps reduce infection risk in cancer patients.

Strength

6 MG

Pack Size

0.6ML

Manufacturer / TM Owner

APOTEX INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Lapelga 6 mg is primarily used to stimulate the production of white blood cells in individuals undergoing chemotherapy. This helps to mitigate the risk of infections, which can be a common side effect of cancer treatment. Pegfilgrastim, the active ingredient, works by supporting the body's natural defenses during periods of immune suppression.

Side Effects

Common effects of Lapelga 6 mg may include bone pain, fatigue, and mild allergic reactions at the injection site. These effects are generally temporary and should be discussed with a healthcare provider if they persist or worsen. Individual responses to the medication can vary.

Precautions & Warnings

Lapelga 6 mg should be handled with care, ensuring proper storage and administration as directed. It is important to follow the prescribed guidelines for subcutaneous injection to minimize the risk of complications. Always consult a healthcare professional for personalized advice.

Avoid Interactions

Lapelga 6 mg may interact with other medications, particularly those that affect the immune system. It is advisable to inform your healthcare provider about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Frequently Asked Questions

Lapelga 6 mg is used to support white blood cell production in individuals undergoing chemotherapy, helping to reduce the risk of infections.

Lapelga 6 mg is administered via subcutaneous injection, typically into the thigh, abdomen, or upper arm.

Common side effects may include bone pain, fatigue, and mild allergic reactions at the injection site.

It is important to consult a healthcare provider before using Lapelga 6 mg with other medications to avoid potential interactions.

Lapelga 6 mg should be stored according to the manufacturer's instructions, typically in a refrigerator, to maintain its efficacy.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.